Results 181 to 190 of about 918,755 (343)
A study exploring predictors of cell phone use while walking among adolescents based on theory of planned behavior. [PDF]
Tang B +8 more
europepmc +1 more source
Effects of the presence of a cell phone and exposure to natural environments on remote associates task performance. [PDF]
Liu W +4 more
europepmc +1 more source
DIGITAL DEPENDENCE: HOW CELL PHONES ARE INFLUENCEING STUDENTS’ BEHAVIOR
Walaci Magnago +9 more
openalex +2 more sources
Objective High intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced SSc. The role of reduced intensity conditioning (RIC) prior to AHSCT in this population remains unclear. We conducted this study to determine the long‐term outcomes of RIC AHSCT in SSc patients with cardiac ...
Yonatan Lean +4 more
wiley +1 more source
An Epidemiological Study of Cell Phone-Related Injuries of the Hand and Wrist Reported in United States Emergency Departments From 2011 to 2020. [PDF]
McLaughlin WM +5 more
europepmc +1 more source
Predictors of short-term decay of cell phone contacts in a large scale communication network [PDF]
Troy Raeder +3 more
openalex +1 more source
Objectives Femoroacetabular impingement (FAI) and synovitis have been recognized as essential factors for developing osteoarthritis (OA) in the hip joints. However, little is known about altered synovial cellular compositions, their associated transcriptomic profiles, and cell‐cell interactions in FAI and hip OA.
Gulzada Kulzhanova +9 more
wiley +1 more source
Nesting on Cell Phone Towers: An Inexplicable Breeding Strategy by Asian Woollynecks <i>Ciconia episcopus</i> in Bangladesh. [PDF]
Sadik AS, Datta AK.
europepmc +1 more source
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate‐to‐severe SLE activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly for 52 weeks (1:1 ...
Susan Manzi +12 more
wiley +1 more source

